Showing Results for: “diabetes exercise”

Research Presented at the ADA’s Scientific Sessions Highlights Need to Address Health Equity to Improve Diabetes Management and Outcomes Today, two studies provide evidence that social determinants of health account for disparities in health outcomes related to diabetes. Both studies were released as poster presentations at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA) in New Orleans, LA. This research comes at a time when individuals with lower socioeconomic status are more likely to develop diabetes, experience more complications, and die sooner than those with a

Exploratory Analysis from the SURPASS-4 Trial Data for Kidney Function with Tirzepatide Compared to Insulin Glargine A pre-specified exploratory analysis from the SURPASS-4 trial showed tirzepatide, a novel once-weekly medication for the treatment of diabetes, improved kidney outcomes for adults with type 2 diabetes who have increased cardiovascular risk. SURPASS-4 was part of the SURPASS global clinical development program for Eli Lilly and Company’s tirzepatide. Findings were presented at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA). Chronic kidney disease (CKD)

Growing reports of dangerous new health conditions, hard-to-manage blood sugar now emerging. A new study released today by the American Diabetes Association® in partnership with dQ&A, finds that growing numbers of people with diabetes have not only been forced to put off needed medical care since the outbreak of COVID-19, but that alarming numbers are struggling to manage their blood glucose levels. Key survey results found: Nearly 1 in 5 Americans with diabetes have skipped doctor’s appointments since the start of the pandemic, principally due to fear of contracting the virus; 1 in 4 people

The American Diabetes Association® (ADA) is honored to announce the recipients of the 2021 National Scientific and Health Care Achievement Awards . The awards recognize academics, health care providers and educators who have contributed to tangible advances in the field of diabetes care and research. Each of these leaders have unwavering dedication to achieving the mission of the ADA: life free of diabetes and all its burdens. “I am thrilled to recognize the eight remarkable individuals receiving the ADA’s National Scientific and Health Care Achievement Awards,” said Tracey D. Brown, Chief

The American Diabetes Association (ADA) welcomes the 2021 Principal Officers and Board of Directors. The 17-member board is comprised of forward-thinking, innovative medical, scientific, education and executive business professionals, who will strategically lead and focus efforts to ensure the ADA continues to uphold the mission upon which it was founded. "I am so excited to announce our 2021 Board of Directors, including five new Board members,” said Tracey D. Brown, Chief Executive Officer of the ADA. “I look forward to the insight and skills that each of these thought leaders will provide

The bill from Rep. Robin Kelly (D-IL) extends protections to low-income and minority communities during COVID-19 The American Diabetes Association® (ADA), the nation’s leading organization for all people living with diabetes, announced its support today for the Ending Health Disparities during COVID-19 (EHDC) Act, introduced by Representative Robin Kelly (D-IL). The list of bill cosponsors includes Reps. Karen Bass (D-CA), Joaquin Castro (D-TX), Judy Chu (D-CA), Jesús “Chuy” García (D-IL), Deb Haaland (D-NM), Barbara Lee (D-CA), Darren Soto (D-FL), Terri Sewell (D-AL), G.K. Butterfield (D-NC)

The diabetes medications glimepiride and linagliptin had similar impacts on cardiovascular morbidity and mortality for a median period of 6.3 years, when added to standard care for people with relatively early type 2 diabetes (T2D), many of whom had an elevated risk of cardiovascular disease (CVD) or existing CVD at the beginning of the study, according to research presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. The study was featured today at “The CAROLINA Trial—First Results of the Cardiovascular

By continuing to follow the cohort from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study sponsored by the National Institutes of Health (NIH), researchers can now report on the extensive development of severe renal, cardiac, eye, nerve, and pregnancy complications in early adulthood in patients with youth-onset type 2 diabetes. Results from this follow up study, TODAY2, presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions®, show an accelerating rate of serious complications within the last five years and point to the increased

Peter Rossing, MD, DMSc, has been selected to receive the American Diabetes Association’s® (ADA’s) 2019 Edwin Bierman Award. This award recognizes a leading scientist who has made outstanding contributions in the field of diabetes-related macrovascular complications and related risk factors. Dr. Rossing will be recognized with this honor during the ADA’s 79th Scientific Sessions, June 7–11, 2019, at the Moscone Convention Center in San Francisco. He will deliver his Edwin Bierman Award Lecture, titled “ Linking Kidney and Cardiovascular Complications—Impact on Prognosis and Treatment ,” on

Assiamira Ferrara, MD, PhD, has been selected to receive the American Diabetes Association’s® (ADA’s) 2019 Norbert Freinkel Award, given in memory of Norbert Freinkel, a dedicated investigator and industry thought leader. The Norbert Freinkel Award honors a researcher who has made outstanding contributions—including scientific publications and presentations—to the understanding and treatment of diabetes in pregnancy. Dr. Ferrara will be recognized with this honor during the ADA’s 79th Scientific Sessions, June 7–11, 2019, at the Moscone Convention Center in San Francisco. She will deliver the